What is PT-141? A Melanocortin Peptide Breakdown
Compound Spotlight
PT-141 is one of very few compounds in this catalog with an approved pharmaceutical form, and it arrived there by an unusual route: it was discovered as a byproduct. Researchers studying a tanning peptide noticed a consistent side effect, traced it to a breakdown product, and developed that metabolite into a drug.
Quick summary
- Also called bremelanotide; a cyclic seven-amino-acid melanocortin receptor agonist.
- Discovered as an active metabolite of Melanotan II during tanning-peptide research.
- Acts centrally in the brain, primarily at the MC4 receptor — not on vascular tissue.
- That central mechanism makes it categorically different from PDE5 inhibitors, which act on blood flow.
- FDA approved in June 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
- An earlier intranasal formulation was halted in development over blood-pressure increases — a real and instructive part of its history.
An accidental discovery
The melanotan program at the University of Arizona in the 1980s aimed at a synthetic alpha-MSH analog that would stimulate melanin production — a “tanning peptide” intended to reduce UV exposure and skin cancer risk. Melanotan II came out of that work.
In testing, Melanotan II produced a consistent and unintended effect: spontaneous erections in male subjects. Rather than treating this as a nuisance, researchers investigated it, and found that the effect tracked to a metabolite formed when Melanotan II is broken down in the body. That metabolite — lacking the C-terminal amide group of the parent molecule — was isolated and developed as PT-141.
The structural change matters: removing that group shifts the receptor selectivity profile away from the MC1 receptor responsible for pigmentation and toward MC4, which mediates the central effects. PT-141 therefore produces substantially less tanning activity than its parent compound.
A central mechanism
This is the most important thing to understand about PT-141, and the point most commonly muddled. PDE5 inhibitors such as sildenafil work peripherally, on vascular smooth muscle, by prolonging nitric oxide signaling to increase blood flow. They act on the plumbing.
PT-141 does not do this. It acts on melanocortin receptors in the central nervous system, principally MC4R in hypothalamic regions involved in sexual motivation. Research points to downstream dopaminergic signaling in the medial preoptic area. It is studied for effects on desire and arousal at the level of neural circuitry rather than on erectile hemodynamics — which is why it was ultimately developed for a desire disorder rather than an erectile one, and why the two drug classes are not substitutes for each other.
The development history, including the setback
PT-141 was initially developed as an intranasal formulation for erectile dysfunction. That program was halted after trials showed dose-dependent increases in blood pressure. This was not a trivial finding — melanocortin receptors are involved in cardiovascular regulation, and the intranasal route produced pharmacokinetics that made the effect difficult to manage.
Development resumed with a subcutaneous formulation and a different target population. In June 2019 the FDA approved bremelanotide as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. The approved labeling carries warnings regarding transient blood pressure increases and advises against use in people with uncontrolled hypertension or known cardiovascular disease. Nausea is the most commonly reported adverse effect and is frequently significant.
The blood-pressure history is worth knowing precisely because it is the sort of detail that gets dropped from commercial descriptions. A compound acting on melanocortin receptors has cardiovascular effects because those receptors have cardiovascular roles — that is mechanism, not bad luck.
Efficacy in context
The approval was based on two randomized placebo-controlled trials in which participants receiving bremelanotide showed statistically significant improvements in desire and distress measures relative to placebo. It is also fair to note that effect sizes in the HSDD trial literature were modest, that placebo response in this area is substantial, and that the outcome instruments are self-reported. Approved does not mean dramatic; it means it cleared a regulatory bar on defined endpoints.
Relationship to the melanotans
PT-141, Melanotan I, and Melanotan II are all melanocortin agonists, but their receptor selectivity differs and so do their dominant effects. Melanotan I (afamelanotide) is relatively MC1R-selective and is approved in some jurisdictions for erythropoietic protoporphyria. Melanotan II is broadly non-selective, which is why it produces both pigmentation and sexual effects along with nausea and flushing. PT-141 is shifted toward MC4R. Treating them as interchangeable because they share a family is a common and consequential error.
Frequently asked questions
How is PT-141 different from sildenafil?
Completely different targets. Sildenafil acts peripherally on vascular smooth muscle to increase blood flow. PT-141 acts centrally on brain melanocortin receptors involved in sexual motivation. They are not the same class and do not work by the same route.
Does PT-141 cause tanning?
Much less than Melanotan II. The structural difference shifts selectivity away from the MC1 receptor that drives pigmentation, though melanocortin agonists are rarely perfectly selective.
Why was the original nasal spray discontinued?
Trials showed dose-dependent blood pressure increases. Development shifted to subcutaneous administration and a different indication, and the approved product still carries blood-pressure-related warnings.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.
References
- Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96–102.
- Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health. 2016.
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899–908.
- US FDA. Vyleesi (bremelanotide) prescribing information. 2019.
View the PT-141 product listing →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. Bremelanotide is approved in the United States only as the prescription product Vyleesi; material sold for research use is not an approved medicine. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
